Nu 3

Drug Profile

Nu 3

Alternative Names: Bisphosphocin Nu-3; Nu-3; Nubiotics

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oligos Etc.
  • Developer Lakewood Amedex
  • Class Antibacterials
  • Mechanism of Action Cell membrane structure modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Diabetic foot ulcer
  • Preclinical Lung disorders
  • No development reported Burn infections; Lyme disease; Onychomycosis; Urinary tract infections

Most Recent Events

  • 27 Sep 2017 Efficacy data from a phase I/II trial in Diabetic foot ulcer released by Lakewood-Amedex
  • 27 Sep 2017 Lakewood-Amedex completes a phase I/II trial in Diabetic foot ulcer (In adults, In the elderly) in USA (Topical) (NCT02737722)
  • 22 Aug 2017 Lakewood Amedex completes enrolment in its phase IIa trial for Diabetic foot ulcer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top